038070 — Seoulin Bioscience Co Balance Sheet
0.000.00%
- KR₩52bn
- KR₩31bn
- KR₩77bn
Annual balance sheet for Seoulin Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 73,282 | 52,794 | 32,878 | 22,358 | 33,866 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 10,333 | 9,578 | 15,509 | 9,591 | 11,240 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 100,846 | 87,287 | 72,955 | 59,841 | 72,035 |
| Net Property, Plant And Equipment | 14,937 | 16,491 | 18,914 | 16,628 | 16,839 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 136,566 | 135,486 | 114,100 | 101,525 | 118,798 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 24,808 | 46,365 | 28,030 | 13,634 | 31,669 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 61,705 | 51,083 | 31,037 | 17,632 | 34,587 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 74,861 | 84,403 | 83,063 | 83,893 | 84,211 |
| Total Liabilities & Shareholders' Equity | 136,566 | 135,486 | 114,100 | 101,525 | 118,798 |
| Total Common Shares Outstanding |